Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginkgo diterpene lactone meglumine injection for acute ischemic stroke (Phase II)
ChiCTR2300070949Phase 2Not yet recruiting
- Sponsor
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Ginkgo diterpene lactone meglumine in ischemic stroke (4 arms), sponsored by Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. Primary endpoints: National Institutes of Health Stroke Scale (NIHSS) and CT perfusion. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
Ginkgo diterpene lactone meglumine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2300070949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070949.